Induction of Labor After Cesarean Using Foley Alone vs. Concurrent Foley and Oxytocin
- Conditions
- Labor InductionCesarean Delivery
- Interventions
- Device: Foley balloon
- Registration Number
- NCT07006896
- Lead Sponsor
- University of Pennsylvania
- Brief Summary
A randomized trial of patients undergoing a term (≥37 weeks) induction of labor with a history of one prior Cesarean delivery, wherein the provider intends to use a Foley catheter for cervical ripening. The investigators will be comparing Foley alone with concurrent Foley and Oxytocin use at the start of the induction. With this trial, the investigators aim to test our central hypothesis that concurrent Foley and Oxytocin will decrease time to delivery without increasing risks, compared to Foley alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 100
- Eligible for induction of labor
- Live singleton gestation ≥37 weeks
- History of 1 cesarean delivery
- ≥18 years of age
- Cephalic presentation
- Intact membranes
- English or Spanish speaking (Able to read/understand consent and instructions)
- Cervical dilation <3cm and Bishop score <8
- >1 prior Cesarean delivery
- Known chorioamnionitis
- Major fetal anomaly
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Concurrent Foley balloon and Oxytocin Foley balloon Cervical ripening will begin with a Foley balloon and concurrent oxytocin, started within 2 hour of balloon placement Concurrent Foley balloon and Oxytocin Oxytocin Cervical ripening will begin with a Foley balloon and concurrent oxytocin, started within 2 hour of balloon placement Foley balloon alone Foley balloon Cervical ripening will begin with a Foley balloon alone. Oxytocin will not be started until the balloon is removed or expelled, though can be considered if the balloon remains in place for \>8 hours
- Primary Outcome Measures
Name Time Method Time to delivery At delivery The primary endpoint will be time from start of induction until delivery (hours)
- Secondary Outcome Measures
Name Time Method Estimated postpartum blood loss At delivery Estimated postpartum blood loss in mL
Postpartum hemorrhage Within 6 weeks of delivery Estimated blood loss≥ 1L
Number of Participants with Chorioamnionitis At delivery Documented chorioamnionitis
Mode of delivery At delivery Successful vaginal birth after cesarean (VBAC) or repeat cesarean delivery (rCD)
Number of Participants with Uterine Rupture At delivery Uterine rupture noted at the time of cesarean delivery
Maternal morbidity Within 6 weeks of delivery Defined as a composite endpoint consisting of at least one occurrence of the following outcomes: postpartum hemorrhage, blood transfusion, endometritis, wound/laceration breakdown or infection, venous thromboembolism and hospital readmission with 6 weeks
Neonatal morbidity Within 6 weeks of delivery Defined as neonatal resuscitation requiring supplemental oxygen outside of the delivery room for at least 12 hours of culture proven/presumed neonatal sepsis
Maternal length of stay From date of delivery to date of discharge from hospital postpartum, up to 6 weeks from delivery Measured by hours from admission to postpartum discharge
Neonatal length of stay From date of delivery to date of discharge from hospital postpartum, up to 6 weeks from delivery Length of stay from birth to discharge, measured in hours
NICU stay greater than 48 hours From date of delivery to date of discharge from hospital postpartum, up to 6 weeks from delivery Admission to the NICU for more than 48 hours
Maternal patient satisfaction as measured by the Hollins Martin Birth Satisfaction scale-Revised (BSS-R) From time of delivery to discharge from hospital, up to 6 weeks from delivery Patient satisfaction as measured by the BSS-R with a possible score of 0-40 with 0 equaling the least birth satisfaction
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Hospital of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Hospital of the University of Pennsylvania🇺🇸Philadelphia, Pennsylvania, United StatesHannah Foster, MDContact267-879-4930hannah.foster@pennmedicine.upenn.edu